Title of article
Coexisting dysbetalipoproteinemia and familial hypercholesterolemia: Clinical and laboratory observations
Author/Authors
Rafael Carmena، نويسنده , , Madeleine Roy، نويسنده , , Ghislaine Roederer، نويسنده , , Anne Minnich، نويسنده , , Jean Davignon، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2000
Pages
12
From page
113
To page
124
Abstract
Type III dysbetalipoproteinemia and familial hypercholesterolemia (FH) are two metabolic disorders giving rise to severe disturbances of lipid homeostasis and premature atherosclerosis. Both metabolic abnormalities have a genetic basis and co-occurrence in the same patient has seldom been described. Because of the unique structure of the French Canadian population, there was an opportunity to observe patients with both dysbetalipoproteinemia (E2/2 homozygotes) and FH (N=14) and to compare their clinical data with that of patients with type III (N=75), patients with FH (N=42). The E2/2-FH patients displayed clinical features of both metabolic disorders: palmar, Achilles and/or extensor tendon xanthomas, a prevalence of coronary artery disease (CAD) equal to that seen in type III, but lower than that observed in FH and a high prevalence of peripheral vascular disease (PVD) in both genders. A higher prevalence of carotid disease than that observed in the two other conditions was seen in women only. In men, total cholesterol level was similar to that observed in FH, but higher than in type III, whereas in women, it was not different among the three groups. In both genders, triglycerides (TG) and low density lipoprotein cholesterol (LDL-C) levels were intermediate between type III and FH, with a very low density lipoprotein-cholesterol (VLDL-C)/TG ratio>0.7 and the presence of β-VLDL on electrophoresis. Presence of a low density lipoprotein receptor, LDL-R, mutation should be suspected in a type III patient with a LDL-C level above 3.0 mmol/l and a family history of premature CAD. In the group of patients studied, the coexistence of dysbetalipoproteinemia and heterozygous FH does not appear to increase the prevalence of cardiovascular complications above that observed among control type III or control E3/3-FH patients. Thus, the presence of two 2 alleles in these patients affects the expression of the abnormal LDL-R allele and the resulting phenotype substantiates the non additive effects of alleles at these two loci (epistasis).
Keywords
familial hypercholesterolemia , Phenotypic expression , Atherosclerotic vascular disease , Dysbetalipoproteinemia
Journal title
Atherosclerosis
Serial Year
2000
Journal title
Atherosclerosis
Record number
629780
Link To Document